Centergate Tech's drug wins national procurement bid

Beijing Centergate Technologies Holding (SZSE:000931) announced that its subsidiary, Duoduo Pharmaceutical, has been selected in the national centralized procurement program for traditional Chinese medicines. Duoduo Pharmaceutical's Acanthopanax Senticosus Injection was chosen during the program. This injection is used for conditions like insufficient liver and kidney function, and has a price of RMB 13.18 per dose. The procurement cycle runs from the date the selection results are implemented until December 31, 2027. During this period, medical institutions will prioritize the selected products and ensure the completion of the agreed purchase volume. The company believes this selection will expand its sales channels, increase market share, and enhance brand influence in the cardiovascular and cerebrovascular disease treatment field. However, Centergate notes that the actual impact on operating performance is still uncertain, and sales may be affected by policy and market changes.